Intelligence Profile
Safety Profile
Safety Profile of Bremelanotide (PT-141)
Evidence Limitation: The provided evidence contains limited specific safety data for bremelanotide. The available information primarily consists of study titles and clinical trial registrations without detailed safety results or adverse event profiles.
Known Side Effects
Based on the available evidence, specific side effect data for bremelanotide is not detailed in the provided materials. The completed Phase 2 and Phase 3 clinical trials (NCT02338960, NCT02333071, NCT01382719) evaluated safety alongside efficacy in premenopausal women, but the actual safety outcomes are not specified in the evidence provided.
Evidence gap: Comprehensive side effect profiles, frequency of adverse events, and severity classifications are not available in the current evidence base.
Contraindications
The provided evidence does not contain specific contraindication information for bremelanotide.
Evidence gap: Absolute and relative contraindications are not detailed in the available materials.
Drug Interactions
No drug interaction data is provided in the available evidence.
Evidence gap: Potential interactions with other medications, including mechanism-based interactions or contraindicated combinations, are not documented in the provided sources.
Special Populations
The clinical trial evidence focuses specifically on premenopausal women with hypoactive sexual desire disorder and/or female sexual arousal disorder. One source mentions consideration for use in men, but safety data for this population is not provided.
Populations with limited evidence:
- Men (safety profile not established in provided evidence)
- Postmenopausal women
- Pregnant or breastfeeding women
- Pediatric populations
- Elderly patients
- Patients with hepatic or renal impairment
Clinical Considerations
The available evidence suggests bremelanotide has been studied in controlled clinical settings through Phase 2 and 3 trials, indicating it has undergone formal safety evaluation. However, the specific results of these safety assessments are not available in the provided materials.
Disclaimer: This safety information is based on limited evidence. Healthcare providers should consult complete prescribing information and conduct thorough patient assessments before considering bremelanotide therapy. Patients should discuss potential risks and benefits with their healthcare provider.
Evidence quality: The safety profile presented here is incomplete due to insufficient detailed safety data in the provided evidence base. More comprehensive safety information would be needed for clinical decision-making.